Amarin Corporation plc (ADR) (OQ:AMRN)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: Gemini House, Bartholomews Walk
DUBLIN FK7 9JQ
Tel: N/A
Website: https://amarincorp.com
IR: See website
<
Key People
Patrick J. Holt
President, Chief Executive Officer, Director
Thomas Charles Reilly
Chief Financial Officer, Executive Vice President, Global Head of HR, Principal Accounting Officer
Stephen B. Ketchum
President - Research and Development, Executive Vice President, Chief Scientific Officer
Jonathan N Provoost
Executive Vice President, Chief Legal and Compliance Officer, Secretary
Aaron D. Berg
Executive Vice President, President - US
 
Business Overview
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Financial Overview
For the fiscal year ended 31 December 2023, Amarin Corporation plc (ADR) revenues decreased 17% to $306.9M. Net loss decreased 44% to $59.1M. Revenues reflect SubTotal decrease of 22% to $285.3M. Lower net loss reflects Selling/General/Admin. Expense decrease of 34% to $187.4M (expense), Stock based compensation expense decrease of 44% to $12.5M (expense), Interest income increase from $2.8M to $11.9M (income).
Employees: 275 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $45.17M as of Dec 31, 2023
Annual revenue (TTM): $306.91M as of Dec 31, 2023
EBITDA (TTM): -$14.42M as of Dec 31, 2023
Net annual income (TTM): -$59.11M as of Dec 31, 2023
Free cash flow (TTM): $6.37M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 401,870,067 as of Feb 23, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.